Literature DB >> 26795946

[Treatment of type 2 diabetes].

J J Meier1.   

Abstract

New glucose-lowering drugs have raised the complexity of diabetes treatment in recent years. While metformin is still the first choice in monotherapy for most cases, various options exist for dual combination therapy. In addition, combinations of three different oral glucose-lowering drugs are increasingly used. Insulin therapy is typically initiated using once daily administration of a long-acting insulin. If basal insulin alone is no longer sufficient, treatment can be intensified by adding short-acting insulin at mealtime or by combining basal insulin with oral glucose-lowering drugs or a glucagon-like peptide (GLP)-1 analogue. The choice of the most appropriate glucose-lowering drug should take into account not only the glucose-lowering efficacy, but also the side effect profile of the respective agents; economic factors must be considered as well. Modern treatment of type 2 diabetes should aim for near-normal glucose control.

Entities:  

Keywords:  Dipeptidyl-peptidase 4 inhibitors; Glucagon-like peptide 1 analogues; Metformin; Sodium-glucose transporter 2 inhibitors; Sulfonylurea compounds

Mesh:

Substances:

Year:  2016        PMID: 26795946     DOI: 10.1007/s00108-015-0002-x

Source DB:  PubMed          Journal:  Internist (Berl)        ISSN: 0020-9554            Impact factor:   0.743


  29 in total

1.  Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus.

Authors:  Benjamin M Scirica; Deepak L Bhatt; Eugene Braunwald; P Gabriel Steg; Jaime Davidson; Boaz Hirshberg; Peter Ohman; Robert Frederich; Stephen D Wiviott; Elaine B Hoffman; Matthew A Cavender; Jacob A Udell; Nihar R Desai; Ofri Mosenzon; Darren K McGuire; Kausik K Ray; Lawrence A Leiter; Itamar Raz
Journal:  N Engl J Med       Date:  2013-09-02       Impact factor: 91.245

2.  The effect of the endoscopic duodenal-jejunal bypass liner on obesity and type 2 diabetes mellitus, a multicenter randomized controlled trial.

Authors:  Parviez Koehestanie; Charlotte de Jonge; Frits J Berends; Ignace M Janssen; Nicole D Bouvy; Jan Willem M Greve
Journal:  Ann Surg       Date:  2014-12       Impact factor: 12.969

3.  Bariatric surgery versus intensive medical therapy for diabetes.

Authors:  Philip R Schauer; Deepak L Bhatt; Sangeeta R Kashyap
Journal:  N Engl J Med       Date:  2014-08-14       Impact factor: 91.245

4.  Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes.

Authors:  Rena R Wing; Paula Bolin; Frederick L Brancati; George A Bray; Jeanne M Clark; Mace Coday; Richard S Crow; Jeffrey M Curtis; Caitlin M Egan; Mark A Espeland; Mary Evans; John P Foreyt; Siran Ghazarian; Edward W Gregg; Barbara Harrison; Helen P Hazuda; James O Hill; Edward S Horton; Van S Hubbard; John M Jakicic; Robert W Jeffery; Karen C Johnson; Steven E Kahn; Abbas E Kitabchi; William C Knowler; Cora E Lewis; Barbara J Maschak-Carey; Maria G Montez; Anne Murillo; David M Nathan; Jennifer Patricio; Anne Peters; Xavier Pi-Sunyer; Henry Pownall; David Reboussin; Judith G Regensteiner; Amy D Rickman; Donna H Ryan; Monika Safford; Thomas A Wadden; Lynne E Wagenknecht; Delia S West; David F Williamson; Susan Z Yanovski
Journal:  N Engl J Med       Date:  2013-06-24       Impact factor: 91.245

Review 5.  Inpatient treatment of type 2 diabetes.

Authors:  Thomas G K Breuer; Juris J Meier
Journal:  Dtsch Arztebl Int       Date:  2012-06-29       Impact factor: 5.594

Review 6.  Possible risk factors for increased suicide following bariatric surgery.

Authors:  James E Mitchell; Ross Crosby; Martina de Zwaan; Scott Engel; James Roerig; Kristine Steffen; Kathryn H Gordon; Trisha Karr; Jason Lavender; Steve Wonderlich
Journal:  Obesity (Silver Spring)       Date:  2013-04       Impact factor: 5.002

7.  Risk of pancreatitis in patients treated with incretin-based therapies.

Authors:  Juris J Meier; Michael A Nauck
Journal:  Diabetologia       Date:  2014-04-11       Impact factor: 10.122

8.  Improvement of metabolic syndrome following intragastric balloon: 1 year follow-up analysis.

Authors:  Nicola Crea; Giacomo Pata; Domenico Della Casa; Luigi Minelli; Giovanni Maifredi; Ernesto Di Betta; Francesco Mittempergher
Journal:  Obes Surg       Date:  2009-06-09       Impact factor: 4.129

9.  Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: a randomized, 52-week, double-blind, active-controlled noninferiority trial.

Authors:  Michael A Nauck; Stefano Del Prato; Juris J Meier; Santiago Durán-García; Katja Rohwedder; Martina Elze; Shamik J Parikh
Journal:  Diabetes Care       Date:  2011-08-04       Impact factor: 19.112

Review 10.  Bariatric Surgery for Type 2 Diabetes Mellitus in Patients with BMI <30 kg/m2: A Systematic Review and Meta-Analysis.

Authors:  Attit Baskota; Sheyu Li; Niharika Dhakal; Guanjian Liu; Haoming Tian
Journal:  PLoS One       Date:  2015-07-13       Impact factor: 3.240

View more
  1 in total

1.  [Severe atypical ketoacidosis due to SGLT2-inhibitor therapy : Two case reports].

Authors:  T G K Breuer; K Kampmann; A Wutzler; C Steinfort; W Uhl; W E Schmidt; J J Meier
Journal:  Internist (Berl)       Date:  2018-03       Impact factor: 0.743

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.